menu
    • menu

    Company profile for Ocular Therapeutix

    NEW Drugs in Dev: 9
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our product pipeline candidates are designed to provide differentiated drug delivery solutions that reduce the complexity and burden of the current standard of...
    Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Our product pipeline candidates are designed to provide differentiated drug delivery solutions that reduce the complexity and burden of the current standard of care by creating sustained release alternatives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ocular TherapeutixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    15 Crosby Drive, Bedford, MA 01730, US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ocutx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ocular Therapeutix To Unveil SOL-1 Phase 3 Wet AMD Trial Results
    Ocular Therapeutix To Unveil SOL-1 Phase 3 Wet AMD Trial Results

    13 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/13/3238349/0/en/Ocular-Therapeutix-to-Announce-Topline-Data-for-SOL-1-Phase-3-Superiority-Trial-in-Wet-AMD-on-Tuesday-February-17-2026.html

    GLOBENEWSWIRE
    13 Feb 2026
    Share Share
    Ocular Therapeutix™ Issues Inducement Grant Per Nasdaq Lr
    Ocular Therapeutix™ Issues Inducement Grant Per Nasdaq Lr

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3234068/0/en/Ocular-Therapeutix-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Ocular Therapeutix Reports Q4, FY 2025 Results & Highlights
    Ocular Therapeutix Reports Q4, FY 2025 Results & Highlights

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232830/0/en/Ocular-Therapeutix-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Ocular Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
    Ocular Reports Inducement Grant Under Nasdaq LR 5635(c)(4)

    23 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/23/3225060/0/en/Ocular-Therapeutix-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    23 Jan 2026
    Share Share
    Ocular Hires Eylea Launch Architect To Challenge Regeneron
    Ocular Hires Eylea Launch Architect To Challenge Regeneron

    23 Jan 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/ocular-drafts-eylea-launch-architect-lead-attack-regenerons-blockbuster

    FIERCE PHARMA
    23 Jan 2026
    Share Share
    Ocular Therapeutix Names Robinson Global as CCO
    Ocular Therapeutix Names Robinson Global as CCO

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222655/0/en/Ocular-Therapeutix-Appoints-David-W-Robinson-as-Global-Chief-Commercial-Officer.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search